

32 Introduction

33 Oxidative stress is a condition caused by the imbalance between the production of
34 reactive oxygen species (ROS) and the cell's capacity to neutralize reactive intermediates and
35 repair the molecular damage they generate ([Pizzino et al., 2017](#)). Interactions between ROS,
36 especially hydroxyl and peroxide radicals, and polyunsaturated fatty acids can produce fatty
37 acid radicals which initiate a cascade of reactions known as lipid peroxidation that eventually
38 result in the formation of the reactive aldehydes malondialdehyde (MDA) and 4-hydroxy-2-
39 nonenal (4HNE) ([Esterbauer et al., 1991](#)). These reactive end products of lipid peroxidation
40 are cytotoxic: MDA can react with guanosine bases in DNA to form the mutagenic DNA adduct
41 M1dG ([Marnett, 1999](#)), while both MDA and 4HNE can form Michael adducts or Schiff bases
42 with thiol and amine groups within proteins ([Ayala et al., 2014](#); [Esterbauer et al., 1991](#)). 4HNE
43 adduct formation has been shown to inactivate many proteins including cytochrome c oxidase
44 and reductase ([Chen et al., 1998](#); [Hwang et al., 2020](#)), and treatment of cells with 4HNE has
45 demonstrated that hundreds of cellular proteins are sensitive to 4HNE adduct formation ([Roe](#)
46 [et al., 2007](#); [Vila et al., 2008](#)).

47
48 Ganglioside-induced differentiation-associated protein 1 (GDAP1) is an emerging
49 member of the glutathione-S-transferase (GST) superfamily of cytoprotective enzymes.
50 GDAP1 is localized to the outer mitochondrial membrane via a C-terminal membrane anchoring
51 sequence ([Wagner et al., 2009](#)), and is highly expressed in peripheral neurons ([Niemann et](#)
52 [al., 2005](#); [Noack et al., 2012](#); [Pedrola et al., 2008](#); [Pedrola et al., 2005](#)), and mutants in *GDAP1*
53 result in types 2K, 4A and 4H of Charcot-Marie-Tooth (CMT), the most common inherited
54 peripheral neuropathy ([Barreto et al., 2016](#); [Theadom et al., 2019](#)). GDAP1 has been proposed
55 to play several roles in mitochondrial physiology including mitochondrial network dynamics and
56 transport ([Cantarero et al., 2021](#); [Civera-Tregon et al., 2021](#); [Niemann et al., 2005](#); [Niemann](#)

57 [et al., 2009](#)), calcium homeostasis ([Gonzalez-Sanchez et al., 2019](#)), and oxidative stress
58 ([Miressi et al., 2021](#); [Niemann et al., 2014](#); [Noack et al., 2012](#)). GDAP1 knockdown favors
59 mitochondrial elongation ([Niemann et al., 2005](#)) and increases the sensitivity of cells to
60 oxidative stress, while overexpression is associated with mitochondrial fragmentation
61 ([Niemann et al., 2005](#); [Niemann et al., 2009](#)) and increased glutathione levels ([Noack et al.,](#)
62 [2012](#)). These results suggest that the function of GDAP1 impacts mitochondrial dynamics and
63 cellular redox state but a molecular mechanism connecting GDAP1 with these functions has
64 remained elusive.

65

66 Canonical GSTs conjugate glutathione (GSH) with the electrophilic center of
67 hydrophobic co-substrates ([Oakley, 2011](#); [Reinemer et al., 1991](#)) including xenobiotics and
68 oxidized lipids, facilitating their transport out of the cell ([Hauck and Bernlohr, 2016](#); [Hayes et](#)
69 [al., 2005](#); [Hayes et al., 1998](#); [Hayes and Strange, 1995](#)). Primary sequence analysis indicates
70 GDAP1 contains two GST domains: a putative glutathione (GSH) binding domain (called the
71 G-site), and an H-site responsible for recognizing hydrophobic substrates in canonical GSTs
72 ([Awasthi et al., 1993](#); [Hayes et al., 2005](#)). Previous structural examination of the GST-like core
73 of GDAP1 demonstrated that while the G-site still adopts a thioredoxin fold, alterations in
74 putative GSH-interacting residues suggest GDAP1 cannot recognize GSH in the canonical
75 orientation ([Googins et al., 2020](#)). This is supported by numerous biochemical observations
76 ([Googins et al., 2020](#); [Huber et al., 2016](#); [Shield et al., 2006](#); [Sutinen et al., 2022](#)) using purified
77 components. Observations of GDAP1 H-site structure have shown that it adopts a fold
78 consistent with the GST family ([Googins et al., 2020](#); [Nguyen et al., 2020](#); [Sutinen et al., 2022](#)),
79 suggesting that it may be capable of binding GST substrates. Screening for biological small
80 molecules identified thapsic acid (also known as hexadecanedioic acid) as a lipid binding
81 partner ([Nguyen et al., 2020](#)). Interestingly, structural characterization of the GDAP1-thapsic

82 acid complex suggests this interaction does not utilize the canonical GST binding pocket, but
83 instead is housed within a separate pocket in the H-site formed by loops near helices 5 and 7
84 ([Nguyen et al., 2020](#)). Thapsic acid is found within the outer mitochondrial membrane
85 ([Pettersen and Aas, 1974](#)) but has not been reported to be a GST substrate, further supporting
86 the hypothesis that GDAP1 functions as a lipid sensitive sensor or receptor ([Googins et al.,](#)
87 [2020](#); [Nguyen et al., 2020](#)). Alternatively, thapsic acid binding may be independent of other
88 binding activities that are housed within the canonical GST binding pocket.

89
90 We have demonstrated that GDAP1 can bind the pan-GST inhibitor ethacrynic acid (EA)
91 which is known to target the canonical GST binding pocket through both biochemical and
92 structural studies ([Awasthi et al., 1996](#); [Awasthi et al., 1993](#); [Cameron et al., 1995](#); [Googins et](#)
93 [al., 2020](#)). Interestingly, EA binding required the α -loop region of GDAP1 (amino acids 145-
94 200), an insertion within the H-site that is unique to GDAP1 ([Estela et al., 2011](#); [Googins et al.,](#)
95 [2020](#); [Marco et al., 2004](#); [Shield et al., 2006](#)). Existing data indicate that 1) the α -loop is all or
96 partially disordered structurally, indicating that there is inherent flexibility in this region of the
97 protein ([Googins et al., 2020](#); [Nguyen et al., 2020](#)); 2) one orientation of the α -loop extends
98 long helices 4 and 5 in a conformation similar to the “tower” domain of lignin ([Helmich et al.,](#)
99 [2016](#); [Nguyen et al., 2020](#)); 3) prediction of GDAP1 structure from AlphaFold suggest the α -
100 loop may adopt a two helical bundle with hinges that allow it to fold over the G- and H-sites,
101 making a direct contact with the G-site and forming a lid that completes the canonical binding
102 pocket ([Jumper and Hassabis, 2022](#)), and 4) the α -loop domain contains a number of CMT
103 causing mutations that are found either within the helical bundle but also near the hinge
104 regions. Thus while GDAP1 appears similar to other GST enzymes in many respects, the
105 identity of a GST-like ligand/substrate and the role of the α -loop in GDAP1 function are both
106 unknown.

107

108 Here we show that GDAP1 specifically recognizes 4HNE, a reactive lipid aldehyde that,
109 in addition to a pathological role in oxidative stress, is now recognized as a lipid second
110 messenger ([Bae et al., 2011](#); [Zarkovic et al., 1999](#); [Zhang and Forman, 2017](#)). This suggests
111 a direct role for GDAP1 in recognizing the products of oxidative stress. We reveal that in
112 addition to binding, GDAP1 can form covalent adducts with 4HNE which can be distinguished
113 from non-covalent binding events. We show that like ethacrynic acid, 4HNE binding requires
114 the α -loop. We find that binding of thapsic acid cannot compete with 4HNE binding suggesting
115 these activities are very likely housed at different locations on the GDAP1 surface. Using x-
116 ray crystallography, we report the structure of GDAP1 containing a T157P mutation found in
117 patients containing CMT4K. The mutant appears to destabilize the α -loop, perhaps by
118 decoupling motions of the lids from binding events canonical GST pocket. In support of this,
119 we observe a >3-fold reduction in 4HNE binding affinity using GDAP1T157P. Together these
120 findings establish 4HNE as a biologically relevant interaction partner for the canonical GST
121 binding pocket that connects GDAP1 function to products of oxidative stress.

122

123

124 Results

125

126 **GDAP1 regulates cellular redox status.**

127

128 GDAP1 was previously implicated in the regulation of cellular redox ([Niemann et al.,](#)

129 [2014](#)). We confirmed that GDAP1 has an impact on cellular redox status and that GDAP1

130 overexpression protects the cells against

131 oxidative stress, using two assays:

132 AlamarBlue and WST-1. AlamarBlue

133 contains resazurin, a non-fluorescent cell-

134 permeable compound that becomes

135 fluorescent when it is reduced to resorufin

136 ([O'Brien et al., 2000](#)). A resorufin buildup

137 in the presence of resazurin is an indicator

138 of reducing activity in the cytoplasm.

139 **Figure 1A** shows that HEK293 cells

140 exposed to AlamarBlue accumulate red

141 resorufin fluorescence in a time-

142 dependent manner, and that the rate of

143 this accumulation is suppressed by the

144 exposure of cells to the prooxidant tetra-


145 Butyl Hydroperoxide (tBHP). This

146 suppression is significantly less

147 pronounced in GDAP1 overexpressing

148 cells, compared with control cells (the

149 graph represents 1 trial, 8 biological



150 replicates). **Figure 1B** (4 trials, 8-16 biological replicates each trial) summarizes the effects of
151 GDAP1 overexpression on the ability of cells to withstand redox shifts induced by tBHP. In
152 control cells, a range of tBHP concentrations causes a significant loss of AlamarBlue response;
153 but this loss is diminished in GDAP1 overexpressing cells (**Figure 1B**).

154

155 WST1 is used to track cell viability, as a
156 measure of mitochondrial dehydrogenase activity
157 ([Stockert et al., 2018](#)). **Figure 1C** shows that tBHP
158 suppresses WST-1 signal, which is consistent with
159 decreased cell mitochondrial activity and cell
160 viability. As with AlamarBlue, the suppression is
161 significantly less pronounced in GDAP1-
162 overexpressing cells. Based on these data, we
163 conclude, in line with the prior evidence ([Miressi et](#)
164 [al., 2021](#); [Niemann et al., 2014](#); [Noack et al., 2012](#)),
165 that GDAP1 has a role protecting cells against
166 oxidative stress.

167

168 **GDAP1 binds 4-hydroxynonenal, the end-product**
169 **of lipid peroxidation.**

170

171 GDAP1-mediated changes in cellular redox
172 state as well as its primary sequence homology to
173 the GST superfamily of protein suggest that GDAP1

174 may be capable of binding products of lipid peroxidation. To test this hypothesis, we purified
175 recombinant mouse GDAP1 Δ TM (amino acids 1-322) as we have previously ([Googins et al.,](#)




Figure 2. GDAP1 binds 4-hydroxynonenal.

A) Binding reactions with GDAP1 and indicated fatty acids or products of oxidative stress. Reactions run on 12% Native PAGE. **B)** Chemical structures of compounds used in this study. **C)** Representative gel of GDAP1 binding reactions titrating 4HNE. **D)** Quantification of 4HNE titrations. Error bars represent standard deviation from 3 independent experiments.

176 [2020](#)). We then used native PAGE to determine if GDAP1 Δ TM could interact with products of
177 lipid peroxidation, focusing on 4HNE and MDA, the two end-products formed by the
178 decomposition of peroxidated lipids ([Esterbauer et al., 1991](#)). The migration of GDAP1 does
179 not change in the presence of MDA, suggesting it does not bind, however, we observe the
180 appearance of slower migrating species upon the addition of 1 mM 4HNE ([Figure 2A](#)),
181 indicating formation of GDAP1-4HNE complexes. The addition of thapsic acid results in a
182 species that migrates slightly faster than GDAP1 alone consistent with previous observations
183 of thapsic acid treatment which was found to reduce GDAP1's radius of gyration ([Sutinen et](#)
184 [al., 2022](#)). We also tested arachidonic and linoleic acids to ask whether GDAP1 could
185 recognize fatty acid precursors of lipid peroxidation. We found no observable binding with
186 these ligands, suggesting that the interaction requires the electrophilic groups at the center of
187 4HNE. Next, we tested binding to trans-2-nonenal (t-2NE) which is similar to 4HNE but does
188 not contain a hydroxyl at the C4 position ([Figure 2B](#)). Interestingly, we find a reduction in the
189 amount of the bound species with GDAP1 in the presence of t-2NE, ([Figure 2A](#)), suggesting
190 that GDAP1 is making a direct interaction with the C4 hydroxyl of 4HNE. In an effort to quantify
191 the binding affinity, we measured complex formation throughout a 4HNE titration series,
192 observing an apparent K_D of 398 +/- 80 μ M ([Figure 2C and D](#)). The membrane concentrations
193 of 4HNE have been observed to reach as high as 4 mM in the under conditions of oxidative
194 stress ([Esterbauer et al., 1991](#); [Koster et al., 1986](#); [Poli et al., 2008](#)) leading us to conclude that
195 GDAP1 is recognizing 4HNE at a biologically relevant concentration. Together, these data
196 suggest that GDAP1 can specifically recognize 4HNE, establishing a new biochemical activity
197 for GDAP1 that directly connects GDAP1 with a known biomarker of oxidative stress ([Zarkovic,](#)
198 [2003](#)).


199

200 **Binding to 4HNE is distinct from 4HNE adduct formation.**

201

202 Increased levels of 4HNE resulting from oxidative stress can result in 4HNE adduct
203 formation, a mechanism known to damage and inactivate proteins, especially those involved
204 in energy production within the mitochondria ([Hwang et al., 2020](#)). We first asked whether
205 exposure to 4HNE can produce similar covalent adducts with GDAP1 using GDAP1 Δ TM.
206 Reactions containing either GDAP1 Δ TM or cofilin1 were incubated with 1 mM 4HNE as in
207 Figure 2, but probed via Western blot using an antibody that specifically recognizes the 4HNE
208 adduct formed by Michael addition to a protein ([Usatyuk et al., 2006](#)). Cofilin1 was tested as
209 this protein was proposed to be a GDAP1 binding partner whose binding to GDAP1 was
210 influenced by the cellular redox state ([Wolf et al., 2022](#)). We do not observe any 4HNE adduct
211 formation for Cofilin-1, however, we do observe robust 4HNE adduct formation for GDAP1 Δ TM
212 ([Figure 3A](#)). To determine the EC₅₀ of this interaction, we monitored adduct formation on
213 GDAP1 as a function of 4HNE titration ([Figure 3C and D](#)). We find that the EC₅₀ for this
214 reaction is 241 ± 52


215 μ M. Since the
216 concentration of
217 4HNE needed for
218 half maximal adduct
219 formation is similar
220 to that needed for
221 the binding events
222 observed via PAGE,
223 we asked whether
224 the slower migrating
225 species observed



226 via native PAGE represented a covalent 4HNE protein adduct or alternatively a traditional non-
 227 covalent protein-ligand interaction. To test this, we performed a 4HNE binding reaction and
 228 monitored the results using both native PAGE and Western blot over the course of 1 hour. As
 229 shown in **Figure 3B**, binding of 4HNE is observed within the first time point and the relative
 230 concentrations of bound and unbound species were unchanged, as would be expected for a
 231 binding reaction that has reached equilibrium. These same time points analyzed by Western
 232 blot showed that while robust adduct formation was possible, formation of GDAP1-4HNE
 233 adducts was not immediate but rather lagged far behind binding. Therefore we conclude that
 234 we can observe two distinct species: a 4HNE adduct which is preceded in time by a canonical
 235 protein-ligand complex.

236
 237 **Binding to 4HNE requires the α -Loop**
 238 **domain in GDAP1.**

239 We next asked which domains within
 240 GDAP1 are needed to support 4HNE
 241 binding and/or adduct formation. We tested
 242 adduct formation using GDAP1 Δ TM as our
 243 point of reference, and then tested further
 244 deletion of the N-terminal extension, HD1,
 245 both HD1 and NT deletions, and deletion of
 246 the α -loop. A diagram of the domain
 247 boundaries and organization is shown in
 248 **Figure 4A**. Our results demonstrate that
 249 deletion of the α -loop results in a severe
 250 reduction in 4HNE adduct formation



251 (Figure 4B). This suggests that either the modification site is found within the α -loop and/or
252 the α -loop contains residues critical for 4HNE binding. Deletion of the α -loop also resulted in a
253 loss of 4HNE binding as detected by native PAGE (Figure 4C). 4HNE binding was still
254 observed for GDAP1 constructs lacking the N-terminal extension (NT) and HD1 domains,
255 suggesting those domains do not impact 4HNE binding (Figure 4C). Together these results
256 suggest that critical determinants for 4HNE recognition reside within the α -loop.

257


258 **Binding of 4HNE and thapsic acid to GDAP1 are not competitive with each other.**

259

260 Thapsic acid has been shown to bind in an H-site pocket distinct from the canonical GST
261 binding pocket with a binding affinity of 45 μ M (Nguyen et al., 2020) (Figure 6A). As the GDAP1
262 H-site contains both 4HNE and thapsic acid binding capacity, we asked whether these
263 molecules compete for the same binding site. Since thapsic acid interacts with GDAP1 with
264 higher affinity than 4HNE, we anticipated that thapsic acid would effectively compete with 4HNE
265 for adduct formation if the two ligands are utilizing the same binding sight. We tested adduct
266 formation under these conditions and found no significant change in levels of 4HNE adduct
267 formation in the presence of thapsic acid, suggesting that access to the site of adduct formation
268 was not altered by the addition of thapsic to the reaction (Figure 5A). Next, we addressed the
269 impact of 4HNE and thapsic acid binding on the GDAP1 protein. To do this, we N-terminally
270 labeled GDAP1 with fluorescein and monitored the effect of adding 4HNE or thapsic acid into
271 the reaction using fluorescence polarization. We first measured fluorescence polarization
272 values throughout a titration of 4HNE (Figure 5B), finding an increase in polarization that is
273 concentration dependent, consistent with an increase in the radius of gyration for GDAP1 upon
274 4HNE addition. Deletion of the α -loop largely blocks this effect, consistent with our earlier
275 findings that the α -loop is required for 4HNE binding (Figure 5B). A similar titration with thapsic

276 acid demonstrated a smaller but reproducible decrease in polarization values, suggesting that
 277 the protein's radius of gyration is decreasing upon thapsic acid binding. The K_D for this effect
 278 is $\sim 34\mu\text{M}$, which is consistent with previous measurements of thapsic acid recognition in its
 279 binding pocket ([Nguyen et al., 2020](#)). Performing the experiment with GDAP1 $\Delta\alpha$ -loop resulted
 280 in nearly identical binding curves, demonstrating that the α -loop has no impact on thapsic acid
 281 binding in this experimental context ([Figure 5C](#)). Next, we pre-incubated GDAP1 ΔTM with 150
 282 μM thapsic acid and asked whether this could compete with 4HNE for binding to GDAP1. As
 283 compared to the vehicle control, thapsic acid pre-incubation resulted in no apparent change in
 284 the ability of GDAP1 to bind 4HNE effect ([Figure 5D](#)). Pre-incubation of GDAP1 ΔTM with 1
 285 mM 4HNE for 15 minutes (conditions in which adduct formation was minimal), followed by a
 286 thapsic acid titration showed that the addition of thapsic acid could not diminish the 4HNE

287 mediated
 288 increase in
 289 polarization
 290 ([Figure 5E](#)).
 291 From this
 292 data, we
 293 conclude
 294 that the
 295 4HNE and
 296 thapsic
 297 binding sites
 298 are
 299 separate,



300 have opposing impacts on GDAP1 structure, and that binding of thapsic acid has no impact on
301 4HNE binding.

302

303 **Structure of GDAP1 Δ TM shows the CMT mutant T157P alters α -loop positioning.**

304

305 Over a hundred separate missense mutations in *GDAP1* have been identified in patients

306 with the GDAP1-type Charcot-

307 Marie-Tooth (CMT) disease

308 ([Ammar et al., 2003](#); [Marco et al.,](#)

309 [2004](#); [Martin et al., 2015](#); [Nelis et](#)

310 [al., 2002](#); [Rzepnikowska and](#)

311 [Kochanski, 2018](#); [Senderek et al.,](#)

312 [2003](#)). Both dominant and

313 recessive mutations have been

314 identified and mutations have

315 been classified into CMT sub-

316 types based on their effect on

317 myelination and nerve conduction

318 velocities ([Senderek et al., 2003](#)).

319 With regard to the structure of

320 GDAP1, many CMT mutations

321 have been identified that strongly

322 cluster on long helices 4 and 5 in a

323 region called the CMT hotspot

324 ([Googins et al., 2020](#)). Recent

Table 1. Data Collection and Refinement

Data collection

Space group	P2 ₁ 2 ₁ 2 ₁
Cell dimensions	
<i>a</i> = <i>b</i> = <i>c</i> (Å)	73.6, 80.1, 85.8
α = β = γ (°)	90
Unique Reflections	12,548
Resolution (Å)	58.5 - 2.82 (2.87-2.82) ^a
<i>R</i> _{pim} (%) ^b	6.2 (35.2)
<i>I</i> / σ <i>I</i>	9.0 (2.2)
Completeness (%)	98.6 (98.6)
Redundancy	4.9 (4.6)
CC(1/2) (%)	99.8 (86.6)

Refinement

Resolution (Å)	58.5 – 2.82 (2.97-2.82)
<i>R</i> _{work} ^c / <i>R</i> _{free} ^d (%)	24.6 / 27.2 (36.5-35.2)
Number of non-H atoms	3702
Avg <i>B</i> -factors (Å ²)	62.8
R.m.s. deviations	
Bond lengths (Å)	0.003
Bond angles (°)	0.52
Ramachandran	
Favored, Allowed, Outliers (%)	97.5, 2.3, 0.2
Clashscore	6

^aValues in parentheses are for highest-resolution shell.

^b $R_{pim} = \sum_h [1/(n_h-1)]^{1/2} * \sum_i |<I_h> - I_{h,i}| / \sum_h \sum_i I_{h,i}$ where *h* represents unique reflections, *i* are their symmetry-equivalents, *n_h* denotes the multiplicity, *<I>* is the average intensity of multiple measurements.

^c $R_{work} = \sum_{hkl} ||F_{obs}(hkl)| - F_{calc}(hkl)|| / \sum_{hkl} |F_{obs}(hkl)|$.

^d*R*_{free} represents the cross-validation *R* factor for 984 reflections against which the model was not refined.


325 structural data on GDAP1 containing two CMT-causing mutants in the CMT hotspot
326 demonstrate that neither alters protein stoichiometry, but instead disturb a network of
327 intermolecular interactions that alter protein stability ([Sutinen et al., 2022](#)). Mutations outside
328 of this CMT hotspot would not be expected to impact this interaction network and have not
329 been explored biochemically or structurally. Towards this end, we crystallized and determined
330 the structure of GDAP1 Δ TM T157P. Details of the structure determination process are
331 described in detail in the Experimental Methods. The crystals contain a pair of GDAP1 proteins
332 in the asymmetric unit in a disulfide linked arrangement similar to that observed for CMT-
333 causing mutants H123R and R120W ([Sutinen et al., 2022](#)). Both proteins are ordered
334 throughout the GST-core which aligns with an r.m.s.d of 0.72 Å over 171 C α atoms. Electron
335 density in loop regions was generally better for chain B which was used for the analysis and
336 figures presented here. Differences between GDAP1-T157P and other GDAP1 structures
337 (experimental and predicted) are focused within two regions: the α -loop and helix α 2 of the G-
338 site. As defined in the literature the α -loop is a sequence motif containing GDAP1 residues
339 145-200 ([Estela et al., 2011](#); [Shield et al., 2006](#)) that is inserted between helices α 4 and α 5 in
340 the H-site (**Figure 6A**). Within the α -loop, residues 154-200 are predicted to fold into a two-
341 helical element (described as helices α 4a α 5a here), flanked by hinge regions (described here
342 as N- and C-hinges) (**Figure 6B**) believed to promote transition of the GDAP1 α -loop between
343 closed and open states([Sutinen et al., 2022](#)). The CMT-causing T157P mutant is located very
344 close to the N-hinge (approximately residue 154), where the rigidity of the introduced proline
345 might be expected to alter α -loop motions (**Figure 6B**). Alternatively, since helix α 4a has
346 already been demonstrated to be highly flexible ([Googins et al., 2020](#); [Nguyen et al., 2020](#);
347 [Sutinen et al., 2022](#)), the proline substitution may simply add destabilize helix α 4a further,
348 leaving helix α 5a unaltered. Here we find that both helices α 4a and α 5a are disordered,
349 suggesting that changes in the N-hinge affect positioning of the entire α -loop. This is consistent

350 with a concerted motion of helices α 4a and α 5a between an extended or “open” position
351 observed previously and a “closed” position as predicted by AlphaFold2.

352

353 In canonical GST enzymes, helix α 2 in the G-site forms one wall of the active site and
354 functions in glutathione recognition. In GST P1, this element has been shown to be flexible
355 and to undergo motions concomitant with binding of its substrates ([Lo Bello et al., 1998](#); [Oakley
356 et al., 1998](#)). Structural predictions from AlphaFold position helix α 2 in an orientation similar to
357 the bound state of GST P1. In GDAP1 T157P, however, we find helix α 2 in an extended
358 position, deep within the canonical binding pocket ([Figure 6C and 6D](#)). This results in an ~70%
359 decrease in the volume of the binding pocket using the 3V cavity calculator ([Voss and Gerstein,
360 2010](#)) ([Figure 6E](#)). We hypothesized that this dramatic change in the pocket would result in a
361 decrease in binding affinity between 4HNE and GDAP1 T157P. We tested this directly by
362 purifying recombinant GDAP1 Δ TM T157P protein and assessing its ability to bind 4HNE via
363 native PAGE under conditions with minimal adduct formation ([Figure 6F](#)). The binding affinity

364 for this interaction is measured at $1330 \pm 259 \mu\text{M}$. From this we can conclude that either, 1)
 365 4HNE interacting residues are housed within the canonical GST binding pocket that these



366 interactions are lost by movement of helix $\alpha 2$ into the pocket, or 2) 4HNE interacting residues
367 are contained within the α -loop and the failure to adopt the “closed” conformation of GDAP1
368 results in a decrease in binding. The degree to which one or both of these conclusions is
369 contributing to 4HNE binding is currently unknown. Lastly, we performed protein thermal shift
370 assays on the GDAP1 Δ TM T157P mutant and found that its thermal transition was very similar
371 to that of wild-type, demonstrating that the loss of 4HNE binding is not the result of an overall
372 loss of stability or folding ([Figure 6G](#)). These data all suggest that the T157P variant of GDAP1
373 has a defect in 4HNE recognition. To validate the role of α -loop in the protective function of
374 GDAP1, we used HEK293 cells stably overexpressing a GFP-tagged GDAP1 α -loop deletion
375 construct ([Figure 6H](#)). Expression was confirmed using GFP fluorescence, and the ability of
376 cells to resist redox changes induced by the prooxidant tBHP was analyzed using AlamarBlue
377 as discussed above. Compared with wild-type GDAP1, cells that overexpress a GDAP1 α -
378 loop deletion construct show significantly reduced protection against tBHP. Together, both our
379 in vitro and cell-based assays show that the α -loop region of GDAP1 plays a critical role in
380 4HNE recognition and GDAP1’s cytoprotective function in the cell.

381

382 Discussion

383

384 GDAP1 activity has been implicated in a variety of mitochondrial functions, including the
385 redox homeostasis ([Noack et al., 2012](#)), the oxidative stress response ([Niemann et al., 2014](#)),
386 and the regulation of mitochondrial network dynamics ([Googins et al., 2020](#); [Huber et al., 2016](#);
387 [Niemann et al., 2005](#); [Pedrola et al., 2008](#); [Pedrola et al., 2005](#)). While the involvement within
388 these pathways seems apparent, a direct molecular connection that establishes a role for
389 GDAP1 has remained elusive. Structural data and sequence homology have all suggested
390 that GDAP1 contains significant similarity to the GST family of detoxifying enzymes ([Marco et](#)
391 [al., 2004](#); [Shield et al., 2006](#)), however it adopts a non-canonical quaternary structure ([Nguyen](#)

392 [et al., 2020](#)), contains unique GDAP1-specific domains, and a role for its active site has not
393 been established ([Googins et al., 2020](#)). Here, we have presented biochemical, structural, and
394 cell-based analyses to define the role of the canonical GST-like binding pocket in GDAP1
395 function.

396

397 We focused on GDAP1's role as a member of the oxidative stress response pathway as
398 this pathway is well established for the GST superfamily of which GDAP1 is a novel member
399 ([Marco et al., 2004](#); [Shield et al., 2006](#)). In this context, we asked whether GDAP1 could
400 interact with the end products of lipid peroxidation, specifically MDA and 4HNE which are both
401 toxic end-products formed by the decomposition of oxidized and peroxidated lipids under
402 conditions of oxidative stress ([Esterbauer et al., 1991](#); [Poli et al., 2008](#)). We determined that
403 GDAP1 specifically recognized 4HNE and that this binding occurs within the canonical GST-
404 like binding pocket. We revealed that the α -loop, a sequence insertion within the H-site that is
405 specific to GDAP1, was required for 4HNE binding. Using xray crystallography, we reveal that
406 disease-causing mutants within the N-hinge region destabilize positioning of GDAP1's α -loop
407 with a concomitant movement of the $\alpha 2$ helix from the G-site into the binding pocket, and
408 establish a connection between these two critical regions of the protein and 4HNE binding.
409 GDAP1 has also been shown to interact with the lipid thapsic acid ([Nguyen et al., 2020](#)),
410 however, we demonstrate here that these binding events occur at separate locations and do
411 not appear to be allosterically linked to each other. The biological role for thapsic acid in
412 GDAP1 function is intriguing but remains unclear.

413

414 The establishment of 4HNE as a GDAP1 binding partner is a significant breakthrough
415 in GDAP1 biology that unlocks several intriguing mechanistic questions. First, we observe both
416 covalent and non-covalent interactions with 4HNE. Our results suggest a role for GDAP1 in

417 responding to 4HNE levels but it is unclear if both modes of interaction participate biologically.
418 It is possible that the slower-forming but longer lasting adduct formation provides a timing
419 mechanism following conditions of oxidative stress. Alternatively, it could modulate GDAP1
420 activity, either positively or negatively, until the 4HNE-adduct can be reversed by increased
421 glutathione levels when redox homeostasis is restored. The mechanism of 4HNE binding and
422 its molecular and cellular consequences are open questions that we are actively pursuing.

423

424 Many CMT-causing mutations have been identified within the “CMT hotspot” located on
425 long helices 4 and 5 ([Cassereau et al., 2011a](#); [Cassereau et al., 2011b](#); [Googins et al., 2020](#);
426 [Rzepnikowska and Kochanski, 2018](#)). Mutants in the hotspot have been suggested to
427 influence the thapsic acid binding region or to alter overall stability ([Nguyen et al., 2020](#); [Sutinen](#)
428 [et al., 2022](#)). Here we present biochemical and structural data on T157P a mutant within the
429 N-hinge region, which is distant and distinct from the CMT hotspot. Our data indicate that
430 changes in positioning of the α -loop and $\alpha 2$ regions are associated with this mutation which is
431 reflected in changes in the 4HNE binding pocket and GDAP1 binding affinity for 4HNE. This
432 data provides a molecular explanation for the capacity of T157P to promote disease and we
433 hypothesize that other CMT causing mutants in the binding pocket (such as S34, S36 or K39)
434 or within the α -loop itself (P153, K161, N178, or L205) might have a similar 4HNE binding
435 defects. Future work will explore the direct connection of these residues to interactions with
436 4HNE.

437

438 **Materials and Methods**

439

440 **Protein Purification.** Coding sequences for mouse *GDAP1* constructs encoding GDAP1 Δ TM,
441 GDAP1 Δ TM T157P, GDAP1 Δ α L, and all other GDAP1 constructs described here, were PCR
442 amplified and cloned into the pKF3 plasmid ([Googins et al., 2020](#)) for bacterial expression with

443 an N-terminal His₁₀-mRuby2 tag which can be removed by cleavage with TEV protease. The
444 resulting proteins retain GGS on their N-terminus. Expression was performed in BL21(DE3)-
445 RIPL *Escherichia coli* cells (Agilent) in LB at room temperature and induced through the
446 addition of 0.2 mM IPTG for ~24 hours. Cells were harvested, resuspended in [200 mM NaCl,
447 20 mM Tris pH8, 40 mM Imidazole pH8, 1 mM Tris(2-carboxyethyl) phosphine (TCEP), 5%
448 glycerol], and lysed by homogenization (Avestin C-3). Insoluble material was removed by
449 centrifugation at 16,000 x *g* and His₁₀-mRuby2-GDAP1 fusion protein captured using nickel
450 affinity chromatography followed by digestion with TEV protease overnight to liberate GDAP1
451 protein from the His₁₀-Ruby tag. A second round of nickel affinity chromatography was then
452 performed to remove the mRuby2-tag and TEV. Additional purification was achieved through
453 anion exchange chromatography, and a final step of gel filtration was used to remove any
454 potential aggregates and lingering contaminants. ThermoFluor of samples indicate a single-
455 phase thermal transition consistent with a folded protein. Coding sequences for Cofilin1 were
456 also cloned into pKF3 and expressed and purified in manner similar to GDAP1.

457

458 **Native PAGE protein-ligand interaction assays.** Analysis of protein-ligand interactions via
459 Poly-acrylamide Gel Electrophoresis was conducted by mixing potential ligands (Indicated
460 ligand at indicated concentration) with GDAP1 protein at a final concentration of 55 μM. The
461 reaction buffer was 50mM Tris pH 8, 50mM NaCl. Incubation times were 15 minutes at room
462 temperature unless indicated. Reactions were loaded using 4x Native loading buffer [200 mM
463 Tris pH 6.8, 50% glycerol] supplemented with 0.5mM β-mercaptoethanol to minimize non-
464 specific 4HNE-protein adducts and run on 12% PAGE for 3.5 hours at 200 volts. Gels were
465 stained with Coomassie stain and imaged using an Amersham Imager 600 (General Electric)
466 transillumination setting and analyzed using FIJI for band intensity. Gels imaged using Sypro

467 Orange were incubated in 7.5% acetic acid with 0.05% SDS for 30 minutes, washed with 7.5%
468 acetic acid, then stained with 2x SYPRO Orange dye (Invitrogen) in 7.5% acetic acid for 30
469 minutes. Sypro stained gels were imaged using an Amersham Imager 600 (General Electric)
470 and analyzed with FIJI-ImageJ ([Schindelin et al., 2012](#)).

471

472 **4HNE modification reactions.** Measurements of 4HNE adduct formation were performed with
473 cofilin1 or the indicated GDAP1 fragment at a final protein concentration of 5 μ M in reaction
474 buffer consisting of [50mM Tris pH 8, 50mM NaCl]. Cofilin1 and GDAP1 Δ TM reaction was
475 incubated with 1 mM 4HNE for 2 hours at room temperature in a manner similar to previous
476 literature regarding cytochrome C modification ([Isom et al., 2004](#)). The exception is during the
477 time course experiment in which reaction times are indicated. Samples were mixed 3:1 with 4x
478 loading buffer (200 mM Tris pH 6.8, 8% SDS, 50 mM EDTA, 0.8% Bromophenol Blue, 50%
479 glycerol) without reducing reagent to preserve 4HNE adducts, and boiled at 100 °C for 5
480 minutes. 200 ng of protein loaded in each well and run on a 15% SDS-PAGE for Western Blot
481 analysis. The SDS-PAGE gel was transferred onto nitrocellulose membrane (Thermo
482 Scientific) that was then treated with 100 mM sodium borohydride (Fisher Chemical) for 20
483 minutes to stabilize 4HNE adducts ([McCormack et al., 2005](#)). Western blotting was performed
484 using a α -4HNE antibody specific to the Michael protein adduct (EMD Millipore Corp.) at a
485 dilution of 1:1000 antibody over night at 4°C. Goat α -Rabbit HRP (Thermo Scientific) was the
486 secondary antibody (1:3000 dilution) for 1 hour at room temperature with intervening wash
487 steps performed with TBST. Modified protein was detected by using SuperSignal West Pico
488 PLUS Chemiluminescent Substrate kit (ThermoScientific) with an Amersham Imager 600
489 (General Electric). Blots were then stripped and re-probed with goat α -GDAP1 (Sigma)
490 polyclonal antibody (1:1000 dilution) overnight at 4°C, followed by rabbit anti-goat HRP

491 secondary antibody (1:3000) for 1 hour at room temperature, with intervening TBST washes
492 and imaged as above. Band Intensities were quantified using FIJI-ImageJ. 4HNE band intensity
493 was normalized against the GDAP1 band intensities. Results were analyzed using PRISM.

494
495 **Fluorescein Labeling of Proteins.** The indicated GDAP1 constructs were N-terminally
496 labeled with fluorescein as in ([Mohan et al., 2013](#)). Briefly, protein was dialyzed into fluorescein
497 labeling buffer (20 mM HEPES pH 7.0, 100 mM NaCl, 8% glycerol) at a final protein
498 concentration of 140 μ M, then incubated with 10x molar excess of Fluorescein (Invitrogen) for
499 2 hours at room temperature. Protein was then dialyzed against (20 mM HEPES pH 8, 200 mM
500 NaCl, 2% Glycerol, 1 mM TCEP) for 4 days with a buffer changes every day, until no free
501 fluorescein could be detected by either PAGE or spectroscopically.

502
503 **Fluorescence Anisotropy.** Analysis of GDAP1 via fluorescence anisotropy was conducted
504 using fluorescein labeled protein at 50 nM supplemented with unlabeled protein to achieve a
505 final concentration of 12.5 μ M. The reaction buffer was 50 mM Tris pH 8 and 50 mM NaCl.
506 Unless indicated, protein was incubated for 30 minutes with the indicated ligand prior to
507 measurement of fluorescence polarization using a Biotek Cytation 5 imaging reader.

508
509 **Crystallography.** GDAP1 Δ TM T157P was purified as described earlier and stored at -80°C
510 prior to crystallization trials. Crystals were obtained using sitting-drop vapor diffusion method
511 at 4°C. 1 μ L of protein at 12.8 mg/ml was added to 1 μ L of well solution containing 0.2 M
512 Ammonium Sulfate, 0.1 M Bis-Tris pH 5.5, and 25% (w/v) PEG3350. Small amorphous looking
513 crystals grew slowly over the course of 6 months. Crystals were soaked in mother liquor
514 supplemented with 15% glycerol and flash frozen in liquid nitrogen prior to data collection.

515 Diffraction data were collected at beamline 31-IDD at Argonne National Labs and processed
516 and scaled to 2.8 Å resolution via AutoPROC ([Vonrhein et al., 2011](#)) using $\| \sigma / I \| > 2.0$ and CC(1/2)
517 > 0.3 as cutoffs. Crystals of GDAP1 Δ TM T157P belong to space group P2₁2₁2₁ with $a=73.59$,
518 $b=80.06$, and $c=85.81$ Å. Phases were estimated via the molecular replacement method using
519 the structure of the GST-like core of GDAP1 as the search model ([Googins et al., 2020](#))
520 (PDBID:6UIH). An initial model was built into density using COOT([Emsley et al., 2010](#)) and
521 further improved through rounds of refinement in Phenix([Adams et al., 2010](#)) and model
522 building in COOT, including simulated annealing in the first refinement step. Positional and
523 group B-factor refinements were used during this process. Model quality was assessed using
524 MolProbity within Phenix. Model and structure factors files for the GDAP1-T157P are deposited
525 in the PDB under PDBID code 8EXZ.

526

527 **Cell culture and stable lines.** HEK293 cells were grown in a 5% CO₂ humidified atmosphere
528 at 37°C in Dulbecco-modified eagle medium supplemented with 10% fetal bovine serum. To
529 generate stable lines, the cells were transfected with cDNA plasmids using the calcium-
530 phosphate method and, 24 hours post-transfection, seeded at low density into 400 mg/ml
531 G418. Colonies were picked by scraping and subcloned into 24-well plates. The expression
532 and transfection rate were confirmed using fluorescent microscopy. Alternatively, the cells were
533 transiently transfected using the calcium-phosphate method and used for experiments within
534 24 to 48 hours post-transfection.

535

536 **Fluorescent measurements in live cells.** The cells were seeded into 96-well plates at high
537 confluency and DMEM was replaced with HEPES-based buffer containing, in mM: 140 NaCl,
538 5 KCl, 1 MgCl₂, 1 CaCl₂, 10 HEPES at pH 7.4 and supplemented with 1 g/l glucose. The

539 AlamarBlue (ThermoFisher Scientific, Waltham, MA, product number DAL1025) staining was
540 performed according to the manufacturer's instructions: 10 μ l of the reagent was added per
541 well and the reading of 560/590 nm fluorescence commenced, using ThermoFisher Fluoroscan
542 plate reader. The data were read every 15 min for 3 hours and each well's readings were
543 normalized to the value recorded at the beginning of the read. The conversion of AlamarBlue
544 into a fluorescent product is suppressed if the environment of the cytoplasm is oxidizing; to
545 quantitatively compare the effects of GDAP1 overexpression and drug application of
546 cytoplasmic redox, all data points were normalized to corresponding time points and
547 concentrations in control, untreated cells.

548

549 WST-1 measurements were performed per manufacturer's (Sigma Aldrich, St Louis,
550 MO, product number 11644807001) instructions: 10 μ l of the reagent was added per well, and
551 the 340 nm absorbance was read using Accuris SmartReader 96 (Accuris Instruments, Edison,
552 NJ). To induce a shift in the cellular redox, the cells were treated with 50-500 μ M tert-Butyl
553 hydroperoxide (tBHP) for 1 hr before the experiment. The data are presented as the percentage
554 of AlamarBlue signal that is lost as a result of tBHP application.

555

556 **Statistical analysis.** Ligand binding and modification curves were fitted using the Specific
557 Binding with Hill slope function of Prism 9 and response curves to ligand interactions obtained
558 from fluorescence polarization assays were fitted to data using the Dose Response (3
559 Parameters) function of Prism 9. It is from these curves that K_D and EC_{50} values were
560 calculated with corresponding SEM variance values. Comparisons of these curves were done
561 using sum-of-squares F test with null hypothesis that all data can be fitted using one curve. If
562 the null hypothesis was rejected at $p < 0.05$, we concluded that the curves were statistically
563 different from each other. AlamarBlue concentration curves were fitted using the Michaelis-

564 Menten function of Prism 9 and compared using extra sum-of-squares F test with null
565 hypothesis that all data can be fitted using one curve. If the hypothesis was rejected at $p < 0.05$,
566 we concluded that the curves are significantly different from each other. Alternatively, pairwise
567 comparison (AlamarBlue and WST-1) was performed using ordinary one-way Anova with
568 multiple comparisons by means of Bartlett's test. $P < 0.05$ was considered significant.

569

570 **Acknowledgements**

571 This research used resources of the Advanced Photon Source, a U.S. Department of Energy
572 (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne
573 National Laboratory under Contract No. DE-AC02-06CH11357. Use of the Lilly Research
574 Laboratories Collaborative Access Team (LRL-CAT) beamline at Sector 31 of the Advanced
575 Photon Source was provided by Eli Lilly Company, which operates the facility. This work was
576 supported by NIH R21 grant NS094860 (K.K.).

577

578 **Competing Interests**

579 The authors declare they have no competing interests related to this work.

580

581 **Author Contributions**

582 A.P.V. and K.K. designed experiments, analyzed the data, and wrote the paper. M.R.G.
583 performed the crystallization and structure determination, as well as the biochemical
584 experiments. A.P.V. analyzed the results of the structural and biochemical experiments.
585 M.R.B., A.O.W. and K.K. performed the cell-based experiments. K.K. analyzed the results of
586 the cell-based experiments.

587

588

589

References

590

591 Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W.,
592 Kapral, G.J., Grosse-Kunstleve, R.W., *et al.* (2010). PHENIX: a comprehensive Python-based system
593 for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* **66**, 213-221.

594 Ammar, N., Nelis, E., Merlini, L., Barisic, N., Amouri, R., Ceuterick, C., Martin, J.J., Timmerman, V.,
595 Hentati, F., and De Jonghe, P. (2003). Identification of novel GDAP1 mutations causing autosomal
596 recessive Charcot-Marie-Tooth disease. *Neuromuscul Disord* **13**, 720-728.

597 Awasthi, S., Singhal, S.S., He, N., Chaubey, M., Zimniak, P., Srivastava, S.K., Singh, S.V., and
598 Awasthi, Y.C. (1996). Modulation of doxorubicin cytotoxicity by ethacrynic acid. *Int J Cancer* **68**, 333-
599 339.

600 Awasthi, S., Srivastava, S.K., Ahmad, F., Ahmad, H., and Ansari, G.A. (1993). Interactions of
601 glutathione S-transferase-pi with ethacrynic acid and its glutathione conjugate. *Biochim Biophys Acta*
602 **1164**, 173-178.

603 Ayala, A., Munoz, M.F., and Arguelles, S. (2014). Lipid peroxidation: production, metabolism, and
604 signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. *Oxid Med Cell Longev* **2014**,
605 360438.

606 Bae, Y.S., Oh, H., Rhee, S.G., and Yoo, Y.D. (2011). Regulation of reactive oxygen species generation
607 in cell signaling. *Mol Cells* **32**, 491-509.

608 Barreto, L.C., Oliveira, F.S., Nunes, P.S., de Franca Costa, I.M., Garcez, C.A., Goes, G.M., Neves,
609 E.L., de Souza Siqueira Quintans, J., and de Souza Araujo, A.A. (2016). Epidemiologic Study of
610 Charcot-Marie-Tooth Disease: A Systematic Review. *Neuroepidemiology* **46**, 157-165.

611 Cameron, A.D., Sinning, I., L'Hermite, G., Olin, B., Board, P.G., Mannervik, B., and Jones, T.A. (1995).
612 Structural analysis of human alpha-class glutathione transferase A1-1 in the apo-form and in
613 complexes with ethacrynic acid and its glutathione conjugate. *Structure* **3**, 717-727.

614 Cantarero, L., Juarez-Escoto, E., Civera-Tregon, A., Rodriguez-Sanz, M., Roldan, M., Benitez, R.,
615 Hoenicka, J., and Palau, F. (2021). Mitochondria-lysosome membrane contacts are defective in
616 GDAP1-related Charcot-Marie-Tooth disease. *Hum Mol Genet* **29**, 3589-3605.

617 Cassereau, J., Casasnovas, C., Gueguen, N., Malinge, M.C., Guillet, V., Reynier, P., Bonneau, D.,
618 Amati-Bonneau, P., Banchs, I., Volpini, V., *et al.* (2011a). Simultaneous MFN2 and GDAP1 mutations
619 cause major mitochondrial defects in a patient with CMT. *Neurology* **76**, 1524-1526.

620 Cassereau, J., Chevrollier, A., Bonneau, D., Verny, C., Procaccio, V., Reynier, P., and Ferre, M.
621 (2011b). A locus-specific database for mutations in GDAP1 allows analysis of genotype-phenotype
622 correlations in Charcot-Marie-Tooth diseases type 4A and 2K. *Orphanet J Rare Dis* **6**, 87.

623 Chen, J., Schenker, S., Frosto, T.A., and Henderson, G.I. (1998). Inhibition of cytochrome c oxidase
624 activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme subunits. *Biochim*
625 *Biophys Acta* **1380**, 336-344.

- 626 Civera-Tregon, A., Dominguez, L., Martinez-Valero, P., Serrano, C., Vallmitjana, A., Benitez, R.,
627 Hoenicka, J., Satrustegui, J., and Palau, F. (2021). Mitochondria and calcium defects correlate with
628 axonal dysfunction in GDAP1-related Charcot-Marie-Tooth mouse model. *Neurobiol Dis* 152, 105300.
- 629 Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development of Coot.
630 *Acta Crystallogr D Biol Crystallogr* 66, 486-501.
- 631 Estela, A., Pla-Martin, D., Sanchez-Piris, M., Sesaki, H., and Palau, F. (2011). Charcot-Marie-Tooth-
632 related gene GDAP1 complements cell cycle delay at G2/M phase in *Saccharomyces cerevisiae* fis1
633 gene-defective cells. *J Biol Chem* 286, 36777-36786.
- 634 Esterbauer, H., Schaur, R.J., and Zollner, H. (1991). Chemistry and biochemistry of 4-hydroxynonenal,
635 malonaldehyde and related aldehydes. *Free Radic Biol Med* 11, 81-128.
- 636 Gonzalez-Sanchez, P., Satrustegui, J., Palau, F., and Del Arco, A. (2019). Calcium Deregulation and
637 Mitochondrial Bioenergetics in GDAP1-Related CMT Disease. *International journal of molecular*
638 *sciences* 20.
- 639 Googins, M.R., Woghiren-Afegbua, A.O., Calderon, M., St Croix, C.M., Kiselyov, K.I., and VanDemark,
640 A.P. (2020). Structural and functional divergence of GDAP1 from the glutathione S-transferase
641 superfamily. *FASEB J* 34, 7192-7207.
- 642 Hauck, A.K., and Bernlohr, D.A. (2016). Oxidative stress and lipotoxicity. *J Lipid Res* 57, 1976-1986.
- 643 Hayes, J.D., Flanagan, J.U., and Jowsey, I.R. (2005). Glutathione transferases. *Annu Rev Pharmacol*
644 *Toxicol* 45, 51-88.
- 645 Hayes, J.D., Pulford, D.J., Ellis, E.M., McLeod, R., James, R.F., Seidegard, J., Mosialou, E.,
646 Jernstrom, B., and Neal, G.E. (1998). Regulation of rat glutathione S-transferase A5 by cancer
647 chemopreventive agents: mechanisms of inducible resistance to aflatoxin B1. *Chem Biol Interact* 111-
648 112, 51-67.
- 649 Hayes, J.D., and Strange, R.C. (1995). Potential contribution of the glutathione S-transferase
650 supergene family to resistance to oxidative stress. *Free Radic Res* 22, 193-207.
- 651 Helmich, K.E., Pereira, J.H., Gall, D.L., Heins, R.A., McAndrew, R.P., Bingman, C., Deng, K., Holland,
652 K.C., Noguera, D.R., Simmons, B.A., *et al.* (2016). Structural Basis of Stereospecificity in the Bacterial
653 Enzymatic Cleavage of beta-Aryl Ether Bonds in Lignin. *J Biol Chem* 291, 5234-5246.
- 654 Huber, N., Bieniossek, C., Wagner, K.M., Elsasser, H.P., Suter, U., Berger, I., and Niemann, A. (2016).
655 Glutathione-conjugating and membrane-remodeling activity of GDAP1 relies on amphipathic C-
656 terminal domain. *Sci Rep* 6, 36930.
- 657 Hwang, H.V., Sandeep, N., Paige, S.L., Ranjbarvaziri, S., Hu, D.Q., Zhao, M., Lan, I.S., Coronado, M.,
658 Kooiker, K.B., Wu, S.M., *et al.* (2020). 4HNE Impairs Myocardial Bioenergetics in Congenital Heart
659 Disease-Induced Right Ventricular Failure. *Circulation* 142, 1667-1683.
- 660 Isom, A.L., Barnes, S., Wilson, L., Kirk, M., Coward, L., and Darley-Usmar, V. (2004). Modification of
661 Cytochrome c by 4-hydroxy- 2-nonenal: evidence for histidine, lysine, and arginine-aldehyde adducts.
662 *J Am Soc Mass Spectrom* 15, 1136-1147.
- 663 Jumper, J., and Hassabis, D. (2022). Protein structure predictions to atomic accuracy with AlphaFold.
664 *Nat Methods* 19, 11-12.

- 665 Koster, J.F., Slee, R.G., Montfoort, A., Lang, J., and Esterbauer, H. (1986). Comparison of the
666 inactivation of microsomal glucose-6-phosphatase by in situ lipid peroxidation-derived 4-
667 hydroxynonenal and exogenous 4-hydroxynonenal. *Free Radic Res Commun* *1*, 273-287.
- 668 Lo Bello, M., Nuccetelli, M., Chiessi, E., Lahm, A., Mazzetti, A.P., Battistoni, A., Caccuri, A.M., Oakley,
669 A.J., Parker, M.W., Tramontano, A., *et al.* (1998). Mutations of Gly to Ala in human glutathione
670 transferase P1-1 affect helix 2 (G-site) and induce positive cooperativity in the binding of glutathione.
671 *J Mol Biol* *284*, 1717-1725.
- 672 Marco, A., Cuesta, A., Pedrola, L., Palau, F., and Marin, I. (2004). Evolutionary and structural analyses
673 of GDAP1, involved in Charcot-Marie-Tooth disease, characterize a novel class of glutathione
674 transferase-related genes. *Mol Biol Evol* *21*, 176-187.
- 675 Marnett, L.J. (1999). Chemistry and biology of DNA damage by malondialdehyde. *IARC Sci Publ*, 17-
676 27.
- 677 Martin, A.M., Maradei, S.J., and Velasco, H.M. (2015). Charcot Marie Tooth disease (CMT4A) due to
678 GDAP1 mutation: report of a Colombian family. *Colomb Med (Cali)* *46*, 194-198.
- 679 McCormack, A.L., Atienza, J.G., Johnston, L.C., Andersen, J.K., Vu, S., and Di Monte, D.A. (2005).
680 Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. *J Neurochem* *93*, 1030-
681 1037.
- 682 Miressi, F., Benslimane, N., Favreau, F., Rassat, M., Richard, L., Bourthoumieu, S., Laroche, C.,
683 Magy, L., Magdelaine, C., Sturtz, F., *et al.* (2021). GDAP1 Involvement in Mitochondrial Function and
684 Oxidative Stress, Investigated in a Charcot-Marie-Tooth Model of hiPSCs-Derived Motor Neurons.
685 *Biomedicines* *9*.
- 686 Mohan, S., Das, D., Bauer, R.J., Heroux, A., Zalewski, J.K., Heber, S., Dosunmu-Ogunbi, A.M.,
687 Trakselis, M.A., Hildebrand, J.D., and Vandemark, A.P. (2013). Structure of a highly conserved
688 domain of Rock1 required for Shroom-mediated regulation of cell morphology. *PLoS One* *8*, e81075.
- 689 Nelis, E., Erdem, S., Van Den Bergh, P.Y., Belpaire-Dethiou, M.C., Ceuterick, C., Van Gerwen, V.,
690 Cuesta, A., Pedrola, L., Palau, F., Gabreels-Festen, A.A., *et al.* (2002). Mutations in GDAP1:
691 autosomal recessive CMT with demyelination and axonopathy. *Neurology* *59*, 1865-1872.
- 692 Nguyen, G.T.T., Sutinen, A., Raasakka, A., Muruganandam, G., Loris, R., and Kursula, P. (2020).
693 Structure of the Complete Dimeric Human GDAP1 Core Domain Provides Insights into Ligand Binding
694 and Clustering of Disease Mutations. *Front Mol Biosci* *7*, 631232.
- 695 Niemann, A., Huber, N., Wagner, K.M., Somandin, C., Horn, M., Lebrun-Julien, F., Angst, B., Pereira,
696 J.A., Halfter, H., Welzl, H., *et al.* (2014). The *Gdap1* knockout mouse mechanistically links redox
697 control to Charcot-Marie-Tooth disease. *Brain* *137*, 668-682.
- 698 Niemann, A., Ruegg, M., La Padula, V., Schenone, A., and Suter, U. (2005). Ganglioside-induced
699 differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for
700 Charcot-Marie-Tooth disease. *J Cell Biol* *170*, 1067-1078.
- 701 Niemann, A., Wagner, K.M., Ruegg, M., and Suter, U. (2009). GDAP1 mutations differ in their effects
702 on mitochondrial dynamics and apoptosis depending on the mode of inheritance. *Neurobiol Dis* *36*,
703 509-520.

- 704 Noack, R., Frede, S., Albrecht, P., Henke, N., Pfeiffer, A., Knoll, K., Dehmel, T., Meyer Zu Horste, G.,
705 Stettner, M., Kieseier, B.C., *et al.* (2012). Charcot-Marie-Tooth disease CMT4A: GDAP1 increases
706 cellular glutathione and the mitochondrial membrane potential. *Hum Mol Genet* *21*, 150-162.
- 707 O'Brien, J., Wilson, I., Orton, T., and Pognan, F. (2000). Investigation of the Alamar Blue (resazurin)
708 fluorescent dye for the assessment of mammalian cell cytotoxicity. *Eur J Biochem* *267*, 5421-5426.
- 709 Oakley, A. (2011). Glutathione transferases: a structural perspective. *Drug Metab Rev* *43*, 138-151.
- 710 Oakley, A.J., Lo Bello, M., Ricci, G., Federici, G., and Parker, M.W. (1998). Evidence for an induced-fit
711 mechanism operating in pi class glutathione transferases. *Biochemistry* *37*, 9912-9917.
- 712 Pedrola, L., Espert, A., Valdes-Sanchez, T., Sanchez-Piris, M., Sirkowski, E.E., Scherer, S.S., Farinas,
713 I., and Palau, F. (2008). Cell expression of GDAP1 in the nervous system and pathogenesis of
714 Charcot-Marie-Tooth type 4A disease. *J Cell Mol Med* *12*, 679-689.
- 715 Pedrola, L., Espert, A., Wu, X., Claramunt, R., Shy, M.E., and Palau, F. (2005). GDAP1, the protein
716 causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with
717 mitochondria. *Hum Mol Genet* *14*, 1087-1094.
- 718 Pettersen, J.E., and Aas, M. (1974). Subcellular localization of hexadecanedioic acid activation in
719 human liver. *J Lipid Res* *15*, 551-556.
- 720 Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V., Squadrito, F., Altavilla, D.,
721 and Bitto, A. (2017). Oxidative Stress: Harms and Benefits for Human Health. *Oxid Med Cell Longev*
722 *2017*, 8416763.
- 723 Poli, G., Schaur, R.J., Siems, W.G., and Leonarduzzi, G. (2008). 4-hydroxynonenal: a membrane lipid
724 oxidation product of medicinal interest. *Med Res Rev* *28*, 569-631.
- 725 Reinemer, P., Dirr, H.W., Ladenstein, R., Schaffer, J., Gallay, O., and Huber, R. (1991). The three-
726 dimensional structure of class pi glutathione S-transferase in complex with glutathione sulfonate at 2.3
727 Å resolution. *EMBO J* *10*, 1997-2005.
- 728 Roe, M.R., Xie, H., Bandhakavi, S., and Griffin, T.J. (2007). Proteomic mapping of 4-hydroxynonenal
729 protein modification sites by solid-phase hydrazide chemistry and mass spectrometry. *Anal Chem* *79*,
730 3747-3756.
- 731 Rzepnikowska, W., and Kochanski, A. (2018). A role for the GDAP1 gene in the molecular
732 pathogenesis of CharcotMarieTooth disease. *Acta Neurobiol Exp (Wars)* *78*, 1-13.
- 733 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S.,
734 Rueden, C., Saalfeld, S., Schmid, B., *et al.* (2012). Fiji: an open-source platform for biological-image
735 analysis. *Nat Methods* *9*, 676-682.
- 736 Senderek, J., Bergmann, C., Ramaekers, V.T., Nelis, E., Bernert, G., Makowski, A., Zuchner, S., De
737 Jonghe, P., Rudnik-Schoneborn, S., Zerres, K., *et al.* (2003). Mutations in the ganglioside-induced
738 differentiation-associated protein-1 (GDAP1) gene in intermediate type autosomal recessive Charcot-
739 Marie-Tooth neuropathy. *Brain* *126*, 642-649.
- 740 Shield, A.J., Murray, T.P., and Board, P.G. (2006). Functional characterisation of ganglioside-induced
741 differentiation-associated protein 1 as a glutathione transferase. *Biochem Biophys Res Commun* *347*,
742 859-866.

- 743 Stockert, J.C., Horobin, R.W., Colombo, L.L., and Blazquez-Castro, A. (2018). Tetrazolium salts and
744 formazan products in Cell Biology: Viability assessment, fluorescence imaging, and labeling
745 perspectives. *Acta Histochem* 120, 159-167.
- 746 Sutinen, A., Nguyen, G.T.T., Raasakka, A., Muruganandam, G., Loris, R., Ylikallio, E., Tynismaa, H.,
747 Bartesaghi, L., Ruskamo, S., and Kursula, P. (2022). Structural insights into Charcot-Marie-Tooth
748 disease-linked mutations in human GDAP1. *FEBS Open Bio*.
- 749 Theadom, A., Roxburgh, R., MacAulay, E., O'Grady, G., Burns, J., Parmar, P., Jones, K., Rodrigues,
750 M., and Impact, C.M.T.R.G. (2019). Prevalence of Charcot-Marie-Tooth disease across the lifespan: a
751 population-based epidemiological study. *BMJ Open* 9, e029240.
- 752 Usatyuk, P.V., Parinandi, N.L., and Natarajan, V. (2006). Redox regulation of 4-hydroxy-2-nonenal-
753 mediated endothelial barrier dysfunction by focal adhesion, adherens, and tight junction proteins. *J*
754 *Biol Chem* 281, 35554-35566.
- 755 Vila, A., Tallman, K.A., Jacobs, A.T., Liebler, D.C., Porter, N.A., and Marnett, L.J. (2008). Identification
756 of protein targets of 4-hydroxynonenal using click chemistry for ex vivo biotinylation of azido and
757 alkynyl derivatives. *Chem Res Toxicol* 21, 432-444.
- 758 Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O., Paciorek, W., Womack, T., and Bricogne,
759 G. (2011). Data processing and analysis with the autoPROC toolbox. *Acta Crystallogr D Biol*
760 *Crystallogr* 67, 293-302.
- 761 Voss, N.R., and Gerstein, M. (2010). 3V: cavity, channel and cleft volume calculator and extractor.
762 *Nucleic Acids Res* 38, W555-562.
- 763 Wagner, K.M., Ruegg, M., Niemann, A., and Suter, U. (2009). Targeting and function of the
764 mitochondrial fission factor GDAP1 are dependent on its tail-anchor. *PLoS One* 4, e5160.
- 765 Wolf, C., Pouya, A., Bitar, S., Pfeiffer, A., Bueno, D., Rojas-Charry, L., Arndt, S., Gomez-Zepeda, D.,
766 Tenzer, S., Bello, F.D., *et al.* (2022). GDAP1 loss of function inhibits the mitochondrial pyruvate
767 dehydrogenase complex by altering the actin cytoskeleton. *Commun Biol* 5, 541.
- 768 Zarkovic, N. (2003). 4-hydroxynonenal as a bioactive marker of pathophysiological processes. *Mol*
769 *Aspects Med* 24, 281-291.
- 770 Zarkovic, N., Zarkovic, K., Schaur, R.J., Stolc, S., Schlag, G., Redl, H., Waeg, G., Borovic, S.,
771 Loncaric, I., Juric, G., *et al.* (1999). 4-Hydroxynonenal as a second messenger of free radicals and
772 growth modifying factor. *Life Sci* 65, 1901-1904.
- 773 Zhang, H., and Forman, H.J. (2017). 4-hydroxynonenal-mediated signaling and aging. *Free Radic Biol*
774 *Med* 111, 219-225.
775